Early positive safety results reported for twice-yearly wet AMD treatment – Healio

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

All three cohorts of a phase 1 clinical trial of patients with wet age-related macular degeneration demonstrated positive 30-day safety results, according to a press release from EyePoint Pharmaceuticals.

The DAVIO trial enrolled 17 patients who received one of three doses of EYP-1901 (Durasert sustained-release technology with vorolanib), a twice-yearly intravitreal anti-VEGF treatment.

Through 30 days of post-dosing follow-up, there were no serious adverse events reported, the release said. Additionally, there were no reported adverse events related to significant intraocular inflammation, reduction in best corrected visual acuity or IOP elevation.

“These early results continue to support our belief in the potential of EYP-1901 to be a safe and effective therapeutic for long-term treatment of wet AMD,” Nancy Lurker, CEO of EyePoint Pharmaceuticals, said in the release. “We are looking forward to releasing interim efficacy results once we have sufficient follow-up data for all dose cohorts in the fourth quarter of this year.”

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.